摘要
恶性肿瘤的分子靶向治疗一直是临床医师关注的焦点。在这些治疗靶点中,人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)信号通路是肿瘤转化研究中最热门的靶点之一。每年需要接受抗HER2靶向治疗的患者多达5000万人,部分患者表现出对抗HER2靶向治疗的原发或继发性耐药,且大多数晚期患者不可避免地因耐药问题出现疾病进展而死亡。因此,深入了解抗HER2治疗的原发性和继发性耐药的潜在机制对于开发新的治疗策略至关重要。本文总结了抗HER2靶向治疗的潜在耐药机制,讨论了克服抗HER2治疗耐药策略的应用前景以及用于治疗HER2阳性患者的新型抗HER2治疗方法的发展现状。
Molecular targeted therapy for cancer has always been the research focus of clinicians.The human epidermal growth factor receptor 2(HER2)signaling pathway is one of the most attractive therapeutic targets in translational oncology research.Every year,up to 50 million patients require anti-HER2 targeted treatment.Some patients exhibit primary or secondary resistance to anti-HER2 targeted therapy,and most advanced patients died inevitably due to disease progression brought on by resistance.Therefore,an in-depth understanding of the underlying mechanisms of primary and secondary resistance to anti-HER2-targeted therapy is crucial for developing new therapeutic strategies.This review has summarized the potential mechanisms of resistance to HER2-targeted therapy and discussed the strategies to overcome anti-HER2 resistance,as well as the development of novel anti-HER2 targeted therapy for HER2 positive patients.
作者
杨晓静
徐溢
沈赞
YANG Xiaojing;XU Yi;SHEN Zan(Department of Radiation Oncology,Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University,Shanghai 200233,China;Department of Oncology,Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University,Shanghai 200233,China)
出处
《肿瘤》
CAS
北大核心
2023年第7期580-597,共18页
Tumor
关键词
HER2
靶向治疗
耐药
HER2
Targeted therapy
Drug resistance
作者简介
Correspondence to:沈赞,E-mail:sshenzzan@vip.sina.com.
